Content overview
CAR detection solutions
Quick product guide
Performance data
Resources
All products
Content
- CAR detection solutions
- Quick product guide
- Performance data
- Resources
- All products
Chimeric antigen receptors (CARs) are engineered proteins that enable T cells to recognize and target cancer cells, making precise detection essential for advancing CAR T cell therapies.
Our CAR detection reagents are engineered with REAfinity® Recombinant Antibody Technology and undergo rigorous quality control throughout development, delivering high precision, exceptional reproducibility, and consistent performance in analytical flow cytometry assays.
Content overview
CAR detection solutions
Quick product guide
Performance data
Resources
All products
Our CAR detection portfolio offers three distinct solution types, each leveraging a different detection strategy to match diverse CAR designs:
All three solution types are compatible with CAR T, CAR NK, and other CAR-engineered cell therapies, supporting flow cytometry assays across all stages of research and cell manufacturing.
| CAR Target | CAR linker antibodies | Antigen-based CAR detection reagents | CAR idiotype antibodies |
| CD19 | CAR Antibody (Whitlow/218 Linker), REAfinity CAR Antibody (G4S Linker), REAfinity | CD19 CAR Detection Reagent, human | CD19 CAR FMC63 Idiotype Antibody, REAfinity |
| BCMA (CD269) | BCMA CAR Detection Reagent, human | ||
| CD22 (siglec 2) | CD22 CAR Detection Reagent, human | ||
| CD33 (siglec 3) | CD33 CAR Detection Reagent, human | ||
| CD123 | CD123 CAR Detection Reagent, human | ||
| GD2 | GD2 CAR 14G2a Idiotype Antibody, REAfinity | ||
| MSLN (mesothelin) | MSLN CAR Detection Reagent, human | ||
| FolR1 (folate receptor 1) | FolR1 CAR Detection Reagent, human | ||
| CD334 | CD334 CAR Detection Reagent, human |
“Working with both antigen-based and anti-idiotype CAR detection reagents, I value the high quality of the REAfinity Technology. Consistent performance over time and the elimination of background allows sensitive detection of CAR+ cells in blood samples as well as tissues by immunofluorescence and ultra-high content imaging. The ready-to-use format and reduced pipetting steps support an efficient workflow.”
Our CAR detection reagents provide high specificity, reproducibility, and sensitivity to CAR cell analysis in analytical flow cytometry assays. Explore the detailed performance data.
The significantly lower background signal and optimal staining performance compared to other vendors, makes our CAR detection reagents ideal for reliable detection of CAR T cells during cell manufacturing and CAR T post-infusion research (not for diagnostic use).
Background-free analysis: All REAfinity Recombinant Antibodies contain a mutated human IgG1 Fc region that abolishes binding to Fcγ receptors. The resultant background-free analysis enables highly specific CAR detection and reliable workflows.
A robust quality control process combined with the advanced REAfinity Recombinant Antibody Technology allows each batch to meet the highest quality standards.
Our CAR detection reagents deliver consistent performance across batches, enabling reproducible detection of CAR+ cells.
Consistent antibody performance: Engineered with REAfinity Technology, our CAR detection reagents deliver minimal lot-to-lot variation, enabling standardized, reliable CAR assays.
Although real-time quantitative polymerase chain reaction (qPCR) is a highly sensitive method to validate the integration of the CAR construct in the T cell genome, it does not assess its functional expression on the cell surface.
Our CAR reagents detect even the lowest levels of CAR+ cells with exceptional sensitivity and accuracy, comparable to qPCR, while providing additional insights into the functionality of these cells.
Multiparameter analysis: Optimized for flow cytometry, our CAR detection reagents offer detailed insights on the presence and phenotype of CAR constructs with high sensitivity and accuracy, while providing the flexibility for multiplexing with additional antibodies for deeper analysis.
Schanda, N. et al. (2021) Cells 10(11):3208. | Read article
Reichman, A. et al. (2022) Int J Mol Sci. 23(2):903. | Read article
Reliable detection of CAR-engineered cells is key at every stage of cell therapy development, from CAR discovery to post-infusion research. Our CAR detection reagents provide precision and consistency, paving the way to successful therapies.
In this webinar, we will delve into the crucial role of flow cytometry in analyzing and characterizing critical quality attributes of CAR T cell products, including identity, purity, and potency, throughout the manufacturing process.
Need a quick solution? Discover Miltenyi Biotec's pretested antibody panels (MBTPs) tailored for precise CAR T cell characterization. Our MBTPs simplify your immunophenotyping workflow, delivering reproducible results for CAR T analysis.
15 products found
|